FY2026 EPS Estimates for Edesa Biotech Reduced by Analyst

Edesa Biotech, Inc. (NASDAQ:EDSA) – Stock analysts at Zacks Research decreased their FY2026 EPS estimates for shares of Edesa Biotech in a note issued to investors on Monday, March 2nd. Zacks Research analyst D. Bautz now expects that the company will earn ($0.97) per share for the year, down from their prior forecast of ($0.94). The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Edesa Biotech in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Edesa Biotech Stock Up 90.8%

EDSA stock opened at $4.35 on Wednesday. The company has a market cap of $36.32 million, a price-to-earnings ratio of -3.78 and a beta of 0.05. Edesa Biotech has a twelve month low of $0.72 and a twelve month high of $4.35. The business has a 50 day moving average price of $1.40 and a two-hundred day moving average price of $1.88.

Edesa Biotech (NASDAQ:EDSA) last released its earnings results on Friday, February 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.28). The company had revenue of $0.10 million during the quarter.

Insiders Place Their Bets

In other Edesa Biotech news, CEO Pardeep Nijhawan purchased 30,000 shares of the stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $2.22 per share, with a total value of $66,600.00. Following the completion of the transaction, the chief executive officer directly owned 371,702 shares in the company, valued at $825,178.44. This represents a 8.78% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna International Group LLP acquired a new position in shares of Edesa Biotech during the 3rd quarter worth approximately $36,000. DRW Securities LLC acquired a new position in shares of Edesa Biotech in the fourth quarter valued at $191,000. State Street Corp bought a new position in shares of Edesa Biotech in the fourth quarter valued at about $27,000. Finally, Diadema Partners LP acquired a new stake in shares of Edesa Biotech during the 4th quarter worth about $77,000. 5.50% of the stock is currently owned by institutional investors.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.